Literature DB >> 18335161

Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease.

Thomas Müller1, Siegfried Muhlack.   

Abstract

Levodopa (LD) application improves motor symptoms and reduces cortisol levels in patients with Parkinson's disease (PD). Endurance exercise enhances cortisol release in proportion to the intensity of the effort and thus may counteract the LD associated cortisol decrease. We measured levels of cortisol and LD over an 1-h long interval following administration of soluble 200 mg LD/50 mg benserazide with concomitant maximal grip strength assessment in 16 PD patients under cued conditions during rest and endurance exercise. The motor response, the plasma levels of cortisol and LD did not significantly differ between both conditions. Cortisol concentrations significantly decreased even during exercise. Grip strength only significantly went up during rest. Endurance exercise did not counteract the LD associated decreased cortisol release. Since cortisol improves muscle function, the lack of increase in maximal grip strength following LD administration during exercise may contribute to reduced exercise capacity, which is reported by PD patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18335161     DOI: 10.1007/s00702-008-0018-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  26 in total

1.  The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa.

Authors:  I Reuter; S Harder; M Engelhardt; H Baas
Journal:  Mov Disord       Date:  2000-09       Impact factor: 10.338

2.  Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum.

Authors:  A Lopez; A Muñoz; M J Guerra; J L Labandeira-Garcia
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

3.  Stress-induced changes in brain serotonergic activity, plasma cortisol and aggressive behavior in Arctic charr (Salvelinus alpinus) is counteracted by L-DOPA.

Authors:  E Höglund; N Kolm; S Winberg
Journal:  Physiol Behav       Date:  2001-10

4.  Force overflow and levodopa-induced dyskinesias in Parkinson's disease.

Authors:  Roland Wenzelburger; Bao-Rong Zhang; Sabine Pohle; Stephan Klebe; Delia Lorenz; Jan Herzog; Henrik Wilms; Günther Deuschl; Paul Krack
Journal:  Brain       Date:  2002-04       Impact factor: 13.501

5.  Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats.

Authors:  P T Männistö; P Tuomainen; M Toivonen; M Törnwall; S Kaakkola
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1990

Review 6.  Steroids.

Authors:  Maggy Riad; Marianna Mogos; Duraiyah Thangathurai; Philip D Lumb
Journal:  Curr Opin Crit Care       Date:  2002-08       Impact factor: 3.687

7.  Does parkinsonian action tremor contribute to muscle weakness in Parkinson's disease?

Authors:  P Brown; D M Corcos; J C Rothwell
Journal:  Brain       Date:  1997-03       Impact factor: 13.501

8.  Influence of repeated levodopa administration on rabbit striatal serotonin metabolism, and comparison between striatal and CSF alterations.

Authors:  D A Loeffler; P A LeWitt; P L Juneau; D M Camp; A J DeMaggio; M K Havaich; P E Milbury; W R Matson
Journal:  Neurochem Res       Date:  1998-12       Impact factor: 3.996

9.  Effect of l-dopa on growth hormone, glucose, insulin, and cortisol response in obese subjects.

Authors:  B Vizner; Z Reiner; M Sekso
Journal:  Exp Clin Endocrinol       Date:  1983-01

10.  Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.

Authors:  Jau-Shin Lou; Greg Kearns; Theodore Benice; Barry Oken; Gary Sexton; John Nutt
Journal:  Mov Disord       Date:  2003-10       Impact factor: 10.338

View more
  3 in total

Review 1.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

2.  Psychological Stress and Changes of Hypothalamic-Pituitary-Adrenal Axis in Patients with "De Novo" Parkinson's Disease.

Authors:  Omer C Ibrahimagic; Amra Cickusic Jakubovic; Dzevdet Smajlovic; Zikrija Dostovic; Suljo Kunic; Amra Iljazovic
Journal:  Med Arch       Date:  2016-12

Review 3.  Relevance of chronic stress and the two faces of microglia in Parkinson's disease.

Authors:  Antonio J Herrera; Ana M Espinosa-Oliva; Alejandro Carrillo-Jiménez; María J Oliva-Martín; Juan García-Revilla; Alberto García-Quintanilla; Rocío M de Pablos; José L Venero
Journal:  Front Cell Neurosci       Date:  2015-08-14       Impact factor: 5.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.